Ostrom QT, Price M, Neff C et al (2023) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2016–2020. Neuro Oncol 25:iv1–iv99. https://doi.org/10.1093/neuonc/noad149

Article  PubMed  PubMed Central  Google Scholar 

Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845–848. https://doi.org/10.1038/359845a0

Article  CAS  PubMed  Google Scholar 

Jensen RL, Ragel BT, Whang K, Gillespie D (2006) Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J Neurooncol 78:233–247. https://doi.org/10.1007/s11060-005-9103-z

Article  CAS  PubMed  Google Scholar 

Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708. https://doi.org/10.1056/NEJMoa1308573

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722. https://doi.org/10.1056/NEJMoa1308345

Article  CAS  PubMed  Google Scholar 

Batchelor TT, Mulholland P, Neyns B et al (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol 31:3212–3218. https://doi.org/10.1200/JCO.2012.47.2464

Article  CAS  Google Scholar 

Ellingson BM, Gerstner ER, Smits M et al (2017) Diffusion MRI phenotypes predict overall survival benefit from Anti-VEGF monotherapy in recurrent glioblastoma: converging evidence from phase II trials. Clin cancer Res Off J Am Assoc Cancer Res 23:5745–5756. https://doi.org/10.1158/1078-0432.CCR-16-2844

Article  CAS  Google Scholar 

Schell M, Pflüger I, Brugnara G et al (2020) Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. Neuro Oncol 22:1667–1676. https://doi.org/10.1093/neuonc/noaa120

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ellingson BM, Sahebjam S, Kim HJ et al (2014) Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma. AJNR Am J Neuroradiol 35:673–679. https://doi.org/10.3174/ajnr.A3748

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patel KS, Yao J, Raymond C et al (2020) Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma. Sci Rep 10:14819. https://doi.org/10.1038/s41598-020-71799-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pope WB, Kim HJ, Huo J et al (2009) Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 252:182–189. https://doi.org/10.1148/radiol.2521081534

Article  PubMed  Google Scholar 

Pope WB, Qiao XJ, Kim HJ et al (2012) Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol 108:491–498. https://doi.org/10.1007/s11060-012-0847-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ellingson BM, Patel K, Wang C et al (2021) Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma. Neuro-oncology Adv 3:vdab082. https://doi.org/10.1093/noajnl/vdab082

Article  Google Scholar 

Ellingson BM, Hagiwara A, Morris CJ et al (2023) Depth of radiographic response and time to tumor regrowth predicts overall survival following Anti-VEGF therapy in recurrent glioblastoma. Clin cancer Res Off J Am Assoc Cancer Res 29:4186–4195. https://doi.org/10.1158/1078-0432.CCR-23-1235

Article  CAS  Google Scholar 

Basser PJ, Mattiello J, LeBihan D (1994) Estimation of the effective self-diffusion tensor from the NMR spin echo. J Magn Reson B 103:247–254

Article  CAS  PubMed  Google Scholar 

Ellingson BM, Malkin MG, Rand SD et al (2010) Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging 31:538–548. https://doi.org/10.1002/jmri.22068

Article  PubMed  PubMed Central  Google Scholar 

Durand-Muñoz C, Flores-Alvarez E, Moreno-Jimenez S, Roldan-Valadez E (2019) Pre-operative apparent diffusion coefficient values and tumour region volumes as prognostic biomarkers in glioblastoma: correlation and progression-free survival analyses. Insights Imaging 10:36. https://doi.org/10.1186/s13244-019-0724-8

Article  PubMed  PubMed Central  Google Scholar 

Sugahara T, Korogi Y, Kochi M et al (1999) Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 9:53–60. https://doi.org/10.1002/(sici)1522-2586(199901)9:1%3C53::aid-jmri7%3E3.0.co;2-2

Article  CAS  PubMed  Google Scholar 

Karavaeva E, Harris RJ, Leu K et al (2015) Relationship between [18F]FDOPA PET uptake, apparent diffusion coefficient (ADC), and proliferation rate in recurrent malignant gliomas. Mol Imaging Biol 17:434–442. https://doi.org/10.1007/s11307-014-0807-3

Article  CAS  PubMed  Google Scholar 

Chenevert TL, Stegman LD, Taylor JM et al (2000) Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92:2029–2036. https://doi.org/10.1093/jnci/92.24.2029

Article  CAS  PubMed  Google Scholar 

Gupta RK, Cloughesy TF, Sinha U et al (2000) Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol 50:215–226. https://doi.org/10.1023/a:1006431120031

Article  CAS  PubMed  Google Scholar 

Hayashida Y, Hirai T, Morishita S et al (2006) Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. AJNR Am J Neuroradiol 27:1419–1425

CAS  PubMed  PubMed Central  Google Scholar 

Lyng H, Haraldseth O, Rofstad EK (2000) Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med 43:828–836. https://doi.org/10.1002/1522-2594(200006)43:6%3C828::aid-mrm8%3E3.0.co;2-p

Article  CAS  PubMed  Google Scholar 

Rose S, Fay M, Thomas P et al (2013) Correlation of MRI-derived apparent diffusion coefficients in newly diagnosed gliomas with [18F]-fluoro-L-dopa PET: what are we really measuring with minimum ADC? AJNR Am J Neuroradiol 34:758–764. https://doi.org/10.3174/ajnr.A3315

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pope WB, Mirsadraei L, Lai A et al (2012) Differential gene expression in glioblastoma defined by ADC histogram analysis: relationship to extracellular matrix molecules and survival. AJNR Am J Neuroradiol 33:1059–1064. https://doi.org/10.3174/ajnr.A2917

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nguyen HS, Milbach N, Hurrell SL et al (2016) Progressing Bevacizumab-Induced diffusion restriction is associated with coagulative necrosis surrounded by viable tumor and decreased overall survival in patients with recurrent glioblastoma. AJNR Am J Neuroradiol 37:2201–2208. https://doi.org/10.3174/ajnr.A4898

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mong S, Ellingson BM, Nghiemphu PL et al (2012) Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls. AJNR Am J Neuroradiol 33:1763–1770. https://doi.org/10.3174/ajnr.A3053

Article  CAS  PubMed